Head-to-head evidence
Cariprazine long-acting injection (Mapi Pharma) vs JX11502MA
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline
Cariprazine long-acting injection (Mapi Pharma)
Developed by Mapi Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07185815 (registry estimate)
JX11502MA
Developed by Zhejiang Jingxin Pharmaceutical Co., Ltd.
NCT06356389 · Phase 1/2 · completed
The study randomized 60 participants to JX11502MA or placebo and used double blinding, but the registry does not report whether the primary safety endpoint was met. Because the results are unavailable, the evidence supports only a limited assessment rather than a definitive conclusion.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine long-acting injection (Mapi Pharma)'s landscape · JX11502MA's landscape